| |
|
|
|
xtalks.com, webinar
Thursday, April 07, 2022 | 11am EDT (NA) / 4pm BST (UK) / 5pm CEST (EU-Central)
Who Should Attend?This webinar will be of interest to the following professionals working on biologics/biosimilars/biobetters: - Research Scientist; Senior Scientist; Principal Scientist; Lead Scientist; Associate Director; Director level scientists
- VP, CMC; VP, R&D; CSO leading biologics/biosimilars/biobetters discovery and development programs
- Academic scientists
- Non-profit organization scientists
What You Will LearnJoin this webinar to learn: - The strategies to shorten timelines while minimizing safety and regulatory risks for biologics development
- Cell line development (CLD) platform options and how testing across multiple platforms simultaneously can help reduce timelines and reduce risks
|
|
|
|
|
|
|
|
Organized by:
|
|
xtalks.com |
|
|
Invited Speakers:
|
|
SpeakerSteven Lang, PhD, MBA, VP, Biologics, Aragen Life SciencesSteven Lang is responsible for Aragen’s bioproduction, cell line development and analytical groups. He was earlier with Genentech’s cell culture department as a director, overseeing research material generation, cell line development, automation and CHO process development, covering activities from DNA to Phase II clinical supplies. In addition to his functional role, Steven led an initiative to modernize the CMC scientific data management processes, which spawned numerous digitization efforts across the global Roche Technical Development network to drive efficiency, transparency and compliance. He also acted as CMC leader for a project team delivering an innovative bispecific antibody into clinical trials. Prior to Genentech, he was with Janssen and Johnson & Johnson. |
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
na
|
|
|
|
|
|
|
|
Registration:
|
|
https://xtalks.com/webinars/accelerating-biologics-development-to-medicines-key-drivers-of-success/
|
|
|
E-mail:
|
|
shunte@xtalks.com
|
|
|
|
|
|
|
|
|
